Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony-stimulating factor presented as a 300 µg/0.5 mL lyophilized powder for solution for injection for intravenous and subcutaneous use. It treats chemotherapy‑induced neutropenia, agranulocytosis, peripheral blood stem cell mobilization, and severe chronic neutropenia in patients requiring neutrophil support.

GNH USA supplies Neupogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neupogen acts as a hematopoietic growth factor to stimulate neutrophil production in several clinical settings.

- Chemotherapy‑induced neutropenia: reduces the duration and severity of neutropenia following cytotoxic therapy. - Agranulocytosis: accelerates recovery of neutrophil counts in patients with severe neutrophil deficiency. - Peripheral blood stem cell mobilization: enhances collection of CD34+ stem cells for transplantation. - Severe chronic neutropenia: provides long‑term support to maintain adequate neutrophil levels.

Neupogen may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Bone pain: discomfort in the limbs or back. - Injection site erythema: redness or mild swelling at the injection site. - Fever: transient elevation of body temperature. - Headache: mild to moderate head discomfort.

Serious or Rare Side Effects: - Splenic rupture: sudden abdominal pain requiring immediate medical attention. - Anaphylaxis: severe allergic reaction with hives, breathing difficulty, or shock. - Capillary leak syndrome: rapid fluid shift causing low blood pressure and edema.

Before initiating therapy, clinicians should consider several safety measures.

- Monitor blood counts: perform regular CBCs to assess neutrophil response. - Assess splenomegaly: evaluate spleen size prior to and during treatment. - Avoid in known hypersensitivity: do not use in patients allergic to filgrastim or excipients. - Use caution in sickle cell disease: monitor for vaso‑occlusive events. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Filgrastim may interact with other agents that affect the immune system or blood cell production.

Major Interactions (Avoid): - Concurrent use with other colony‑stimulating factors (e.g., sargramostim) may increase risk of excessive leukocytosis. - Combination with high‑dose corticosteroids may blunt the neutrophil‑stimulating effect.

Moderate Interactions (Monitor Closely): - Co‑administration with cytotoxic chemotherapy may alter timing of neutrophil recovery. - Use with anticoagulants may increase bleeding risk if thrombocytopenia occurs. - Concurrent antibiotics that affect bone marrow function should be monitored.